CTLA4 and prostate cancer: Analysis of tumor biopsies from stage-matched untreated and ipilimumab or tremelimumab treated patients with bladder cancer, prostate cancer, and metastatic melanoma revealed that patients treated with anti-CTLA-4 agents did not show a decrease of intra-tumoral FOXP3+ T-cells [69,70].